RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20171850
DO 10.1101/2020.08.10.20171850
A1 Sanne Jespersen
A1 Susan Mikkelsen
A1 Thomas Greve
A1 Kathrine Agergård Kaspersen
A1 Martin Tolstrup
A1 Jens Kjærgaard Boldsen
A1 Jacob Dvinge Redder
A1 Kent Nielsen
A1 Anders Mønsted Abildgaard
A1 Henrik Albert Kolstad
A1 Lars Østergaard
A1 Marianne Kragh Thomsen
A1 Holger Jon Møller
A1 Christian Erikstrup
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171850.abstract
AB Objectives The objective of this study was to perform a large seroprevalence survey on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Danish healthcare workers to identify high risk groups.Design Cross-sectional survey.Setting All healthcare workers and administrative personnel at the seven hospitals, pre-hospital services and specialist practitioner clinics in the Central Denmark Region were invited by e-mail to be tested for antibodies against SARS-CoV-2 by a commercial SARS-CoV-2 total antibody enzyme-linked immunosorbent assay (ELISA, Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China).Participants A total of 25,950 participants were invited. Of these, 17,987 (69%) showed up for blood sampling, and 17,971 had samples available for SARS-CoV-2 antibody testing.Main outcome measures 1) Prevalence of SARS-CoV-2 antibodies; 2) Risk factors for seropositivity; 3) Association of SARS-CoV-2 RNA and antibodies.Results After adjustment for assay sensitivity and specificity, the overall seroprevalence was 3.4% (CI: 2.5%-3.8%). The seroprevalence was higher in the western part of the region than in the eastern part (11.9% vs 1.2%, difference: 10.7 percentage points, CI: 9.5-12.2). In the high prevalence area, the emergency departments had the highest seroprevalence (29.7%) while departments without patients or with limited patient contact had the lowest seroprevalence (2.2%). Multivariable logistic regression analysis with age, sex, and profession as the predictors showed that nursing staff, medical doctors, and biomedical laboratory scientists had a higher risk than medical secretaries, who served as reference (OR = 7.3, CI: 3.5–14.9; OR = 4., CI: 1.8–8.9; and OR = 5.0, CI: 2.1–11.6, respectively).Among the total 668 seropositive participants, 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive RT-PCR result. A total of 98% of individuals who had a previous positive viral RNA test were also found to be seropositive.Conclusions We found large differences in the prevalence of SARS-CoV-2 antibodies in staff working in the healthcare sector within a small geographical area of Denmark and signs of in-hospital transmission. Half of all seropositive staff had been tested positive by PCR prior to this survey. This study raises awareness of precautions which should be taken to avoid in-hospital transmission. Additionally, regular testing of healthcare workers for SARS-CoV-2 should be considered to identify areas with increased transmission.Trial registration The study is approved by the Danish Data Protection Agency (1-16-02-207-20).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Wantai tests were donated by The Danish Health Authority requisitioned through Statens Serum Institut. The Central Denmark Region supported the study. The funders had no role in analyzing the results of this study. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the Danish Data Protection Agency (1-16-02-207-20) and by the Central Denmark Region. The regional scientific ethics committee of the Central Denmark Region concluded that this study did not require a scientific ethical approval (request no. 127 on ref. no. 1-10-72-1-20). The SARS-CoV-2 antibody screening was performed at the request of the Danish Health Authority and the Danish Administrative Regions. Only consenting staff were tested and informed about their result All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request.